Company intelligence / Profile preview

Islet Sciences

United States

Ownership: Private
Development stage: Other

Overview

Islet Sciences developed patented technologies for islet cell transplantation and early DNA-based diagnosis of insulin-dependent diabetes, including a program using microencapsulated porcine islets intended for human studies. Evidence included successful animal studies and aim to enter first-in-human trials. The company also acquired DiaKine Therapeutics to expand into anti-inflammatory drugs for diabetes. No Phase 1 clinical trial initiation or commercial products have been reported.

Therapeutic areas: EndocrinologyImmunology
Modalities: Cell therapyDiagnosticSmall molecule
Industry: Biotech

Partnerships

NeoStem/Progenitor Cell Therapy (manufacturing partner)

Beyond the preview

Go deeper on Islet Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Islet Sciences.

Explore the full profile